IMPAX Cancels Scheduled Presentation at UBS Global Specialty Generic Pharmaceuticals Conference

May 28, 2008

HAYWARD, Calif.--(BUSINESS WIRE)--May 28, 2008--IMPAX Laboratories, Inc. (OTC: IPXL) today announced that due to urgent priorities associated with the recent revocation of the registration of the Company's common stock under section 12(g) of the Securities and Exchange Act of 1934, the Company finds it necessary to cancel its previously announced presentation at the UBS Global Specialty and Generic Pharmaceuticals Conference on Thursday, May 29th, at 10:00 a.m. London GMT (5:00 a.m. ET).

About IMPAX Laboratories, Inc.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and markets its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at:

CONTACT: IMPAX Laboratories, Inc.
Larry Hsu, Ph.D., President & CEO
510-476-2000, Ext. 1111
Arthur A. Koch, Jr., Sr. VP & CFO
Mark Donohue, Sr. Director IR
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
Bruce Voss, 310-691-7100

SOURCE: IMPAX Laboratories, Inc.